merck & co. news - Search News

Merck Gets China Nod on HPV Shot for Men

Merck says HPV vaccine for men approved by China's drug regulator

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration, providing a much-needed boost to the company in a key market.

Bloomberg L.P. · 11h

Merck Gets China Nod on HPV Shot for Men Amid Sales Slump

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the US drug giant after a rush among women to get the shot lost steam.

Joplin Globe · 3h

Merck’s GARDASIL® Receives Expanded Approval for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) of China approved GARDASIL ® [Human Papillomavirus Quadrivalent (Types 6,

Reuters on MSN · 1h

Merck's HPV vaccine gets China approval for men amid declining sales

Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a much-needed boost in a key market where demand has been falling among women.

Merck, Wuxi Biologics

Reuters · 1d

China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict business for Chinese biotech companies.

Bloomberg L.P. · 1d

WuXi Bio to Sell Vaccine Facility to Merck for $500 Million

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.

YAHOO!Finance · 1d

Merck to buy WuXi Biologics' Irish vaccine facility for $500 million

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland to MSD International, a subsidiary of Merck & Co. for approximately $500 million.

24/7 Wall St. on MSN1h

Merck Just Paid Investors: How Much Did They Receive?

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...

bovnews1h

What’s Fueling Merck & Co Inc (MRK) Stock’s -13.49% Loss Below Its 200-Day SMA?

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...

17h

Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains

This was the stock's second consecutive day of gains.

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...

21h

Unpacking the Latest Options Trading Trends in Merck & Co

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

14h

Truist Financial downgrades Merck & Company (MRK) to a Hold

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

11h

Merck says its HPV vaccine for men was approved by China's drug regulator

U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

Zacks.com on MSN1d

Merck (MRK) Rises Higher Than Market: Key Facts

Merck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Merck Gets China Nod on HPV Shot for Men

Merck, Wuxi Biologics

Related topics